Pyxis Oncology (NASDAQ:PYXS) Price Target Raised to $8.00

Pyxis Oncology (NASDAQ:PYXS) had its price target boosted by HC Wainwright from $7.00 to $8.00 in a research note issued to investors on Thursday, Marketbeat Ratings reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price would indicate a potential upside of 136.69% from the stock’s current price.

A number of other research firms also recently weighed in on PYXS. Wedbush restated an “outperform” rating and set a $8.00 price target on shares of Pyxis Oncology in a research report on Thursday. Leerink Partners reduced their price objective on Pyxis Oncology from $9.00 to $7.00 and set an “outperform” rating on the stock in a research report on Thursday, July 2nd. Weiss Ratings cut Pyxis Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. Wall Street Zen downgraded Pyxis Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, Wells Fargo & Company upped their target price on Pyxis Oncology from $12.00 to $19.00 and gave the stock an “overweight” rating in a research note on Wednesday. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $8.75.

Pyxis Oncology Price Performance

Shares of NASDAQ:PYXS opened at $3.38 on Thursday. The company’s fifty day moving average price is $3.01 and its 200-day moving average price is $2.22. The firm has a market capitalization of $281.93 million, a price-to-earnings ratio of -2.40 and a beta of 1.34. Pyxis Oncology has a one year low of $1.03 and a one year high of $5.55.

Pyxis Oncology (NASDAQ:PYXS) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). As a group, equities research analysts expect that Pyxis Oncology will post -1.21 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Bank of America Corp DE lifted its stake in shares of Pyxis Oncology by 20.3% in the 4th quarter. Bank of America Corp DE now owns 53,745 shares of the company’s stock valued at $84,000 after acquiring an additional 9,062 shares during the last quarter. Acadian Asset Management LLC bought a new position in Pyxis Oncology during the 1st quarter worth approximately $81,000. XTX Topco Ltd purchased a new position in Pyxis Oncology in the 2nd quarter worth approximately $40,000. Marshall Wace LLP purchased a new position in Pyxis Oncology in the 2nd quarter worth approximately $163,000. Finally, Qube Research & Technologies Ltd lifted its position in Pyxis Oncology by 128.4% in the second quarter. Qube Research & Technologies Ltd now owns 103,063 shares of the company’s stock valued at $113,000 after purchasing an additional 57,935 shares during the last quarter. Hedge funds and other institutional investors own 39.07% of the company’s stock.

More Pyxis Oncology News

Here are the key news stories impacting Pyxis Oncology this week:

• Positive Sentiment: MICVO produced encouraging Phase 1 results. In patients with second-line-and-beyond recurrent/metastatic head and neck squamous cell carcinoma, micvotabart pelidotin (MICVO) generated a 36% confirmed objective response rate, a 94% disease-control rate, median progression-free survival of 6.2 months and a 79% probability of overall survival at 12 months. Responses were observed across HPV status and prior-treatment groups. Pyxis Oncology Announces Positive Updated MICVO Data
• Positive Sentiment: The company plans to advance MICVO into pivotal testing. Pyxis said the data support a Phase 3 Headliner trial in this cancer setting, expected to begin in mid-2027. It also reported no new safety signals, while dose capping reduced the frequency and severity of adverse events among higher-weight patients. Pyxis Oncology Reports 36% Response Rate
• Positive Sentiment: Analyst support remains favorable. Wells Fargo raised its PYXS price target to $19 from $12 and maintained an “overweight” rating. The company also received a broader “Moderate Buy” consensus rating, although analyst targets remain highly speculative for a clinical-stage biotechnology company. Wells Fargo Raises Pyxis Oncology Price Target
• Neutral Sentiment: Management changes provide continuity but add another transition point. Thomas Civik, previously interim CEO, was appointed CEO and chairman, while co-founder John Flavin became lead independent director. Civik’s experience includes leadership roles at Five Prime Therapeutics and other acquired biotechnology companies. Pyxis Oncology Appoints Thomas Civik
• Negative Sentiment: The market reaction highlights lingering development risk. PYXS declined after the update even though the headline results were positive, likely because the evidence remains Phase 1, the study is early and potentially limited in size, and the Phase 3 program is not expected to start until 2027. Investors will also await durability data and results from the MICVO-pembrolizumab combination study expected in the fourth quarter of 2026. Pyxis Oncology Shares React to MICVO Results

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.